Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Operating Expenses (2021 - 2025)

Aligos Therapeutics' Operating Expenses history spans 5 years, with the latest figure at $22.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 3.73% year-over-year to $22.0 million; the TTM value through Dec 2025 reached $90.2 million, down 3.15%, while the annual FY2025 figure was $90.2 million, 3.15% down from the prior year.
  • Operating Expenses reached $22.0 million in Q4 2025 per ALGS's latest filing, down from $29.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $38.3 million in Q4 2021 to a low of $19.5 million in Q2 2025.
  • Average Operating Expenses over 5 years is $26.6 million, with a median of $26.1 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: crashed 33.38% in 2022, then soared 35.99% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $38.3 million in 2021, then tumbled by 31.57% to $26.2 million in 2022, then rose by 9.38% to $28.7 million in 2023, then dropped by 26.1% to $21.2 million in 2024, then increased by 3.73% to $22.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Operating Expenses are $22.0 million (Q4 2025), $29.1 million (Q3 2025), and $19.5 million (Q2 2025).